Request Demo
Last update 29 Mar 2025
MB-102(Mustang Bio, Inc.)
Last update 29 Mar 2025
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms MB-102 |
Target |
Action modulators |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators), T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with MB-102(Mustang Bio, Inc.)NCT02159495
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
100 Clinical Results associated with MB-102(Mustang Bio, Inc.)
Login to view more data
100 Translational Medicine associated with MB-102(Mustang Bio, Inc.)
Login to view more data
100 Patents (Medical) associated with MB-102(Mustang Bio, Inc.)
Login to view more data
100 Deals associated with MB-102(Mustang Bio, Inc.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Biphenotypic Leukemia | Phase 1 | United States | 15 Dec 2015 | |
| Adult Acute Lymphocytic Leukemia | Phase 1 | United States | 15 Dec 2015 | |
| Adult Acute Myeloblastic Leukemia | Phase 1 | United States | 15 Dec 2015 | |
| Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 1 | United States | 15 Dec 2015 | |
| Refractory acute myeloid leukemia | Phase 1 | United States | 15 Dec 2015 | |
| Relapsing acute myeloid leukemia | Phase 1 | United States | 15 Dec 2015 | |
| Residual Neoplasm | Phase 1 | United States | 15 Dec 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT02159495 (AACR2020) Manual  | Phase 1 | 9 | (AML) | gezsotodhy(cygxiffnmm) = ldtmkwzgxl ssnvgztwuy (feeyvokqfg ) View more | Positive | 01 Apr 2020 | |
(BPDCN) | pmoqtztpxd(axavktunfg) = azoyzyfjsk ofjdtrbrmp (spfirjkrbe ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free